Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
about
Pancreatic regulation of glucose homeostasisPituitary Adenlylate Cyclase Activating Peptide Protects Adult Neural Stem Cells from a Hypoglycaemic milieuSafety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.Severe Hypoglycemia Among Patients With Type 2 Diabetes Requiring Emergency Hospital Admission: The HIPOS-ER Study.Trajectories in glycemic control over time are associated with cognitive performance in elderly subjects with type 2 diabetesUse of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA StudyRisk of hypoglycaemia in type 2 diabetes patients under different insulin regimens: a primary care database analysisDosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetesGlycemic Control in Chinese Patients with Type 2 Diabetes Mellitus Receiving Oral Antihyperglycemic Medication-Only or Insulin-Only Treatment: A Cross-Sectional SurveyHypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes.Trends in adherence to dietary recommendations among Korean type 2 diabetes mellitus patients.A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database.Secular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013.Linagliptin as add-on therapy to insulin for patients with type 2 diabetesExperience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during RamadanInsulin plus incretin: A glucose-lowering strategy for type 2-diabetes.A review of gliptins for 2014.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.The role of patient education in the prevention and management of type 2 diabetes: an overview.Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.Cost of severe hypoglycaemia in nine European countries.Incidence and cost of hypoglycemic events requiring medical assistance in a hospital setting in Denmark.Cultural Differences and Considerations When Initiating Insulin.Treatment Outcomes and Tolerability Following Initiation of GLP-1 Receptor Agonists Among Type 2 Diabetes Patients in Primary Care Practices in Germany.Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience.Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.Participation in a National Lifestyle Change Program is associated with improved diabetes Control outcomes.Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014.Hypoglycaemia in diabetes: do we think enough of the cause? An observational study on prevalence and causes of hypoglycaemia among patients with type 2 diabetes in an out-patient setting in Sri Lanka.Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetesAddressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review
P2860
Q26766485-7ED19CFC-90A0-4D8E-9056-47F5ACBF82CAQ27341805-3E0D8F63-63D1-460F-A862-59E0A2BC9B75Q30827022-59E1EFF1-B8B5-4CD4-B4A6-39A3131338DBQ33168702-A617225B-70D6-486F-879B-A757587B000EQ33699538-3D4372BE-C467-4007-BC07-AC5CE26471D2Q33785141-1FA44281-B8E4-4CD3-ACCD-AE0D2E2D7DA3Q35028854-84BC513C-78D5-4B4A-9F70-B7B9358EA95EQ35766301-BB7F12CC-C950-47F4-989D-2284C34BBD8FQ35772606-2613A2AB-2CA2-4C54-98C3-2E27FFB88C13Q36173012-CAB966F4-50FA-4B44-8744-0370AA60AA97Q36340111-439B2E2F-0014-409D-85E5-1F7E8462A84BQ36924024-047C2B9B-B3CD-4B27-915E-C84DDC9D810FQ37101608-A2000C0D-31AA-4607-A833-7CCC5298083AQ37194308-D8A91026-6F2E-4A76-800F-9F529090E853Q37233958-3F37EFFD-274F-4B19-93CB-3868D491F68AQ37281205-369F7F3A-135A-4CBF-B62C-3789111E487EQ37427512-B9434F06-9C4F-4050-A6A7-69137412070BQ37598881-AD53A074-3F3A-45D6-8E61-DAB8A5949EFAQ38266290-B0344468-3A60-4D08-8CB0-4CD794D98F1EQ38335751-AEF2C057-4734-4D08-9188-36D58619CD03Q38614591-EC4EE3C0-CF25-4C49-9B07-7266198C0F4FQ38647717-FFD064A1-88D4-4FAC-B159-A862925C7BC9Q39027188-53197793-7C45-4861-8DE4-6883B9F1DE7CQ39350860-9A2AA094-E3E0-4FB8-9C0C-6378445873D6Q39779773-65C85E73-23C2-40BB-9BB5-2FB72984BB4FQ39842123-72FEDF91-F38E-4D77-914A-DF45F94EB23BQ40955429-E402330D-E18D-48B5-A26E-27698F62450EQ41086086-1F13677B-2810-49F8-B967-78FD60CE0967Q47149556-2D1F9C23-2FFA-4F57-9552-C48F3EE61F25Q47557627-E6D13657-DF50-41C5-8A0A-4D20C93AC68AQ47837747-E2BF3A5E-9662-43BD-8FAC-05C1D82D93D9Q48031376-3F19B6E6-4D52-4CE4-800C-A81B109E014AQ51373669-1277D07C-A7FD-4314-A6D3-C37F8F7DE267Q53832210-B0C797E2-EDF5-4ECE-95A2-3BBBFA746C7DQ55476876-348A3F03-E263-4CC1-84AA-B7FFF0AEF053Q57563922-2C8F3443-C18B-4C12-A36D-65C2D89773D4Q58099964-C7D2725A-FB94-4F4E-89ED-F7F7F48E7244
P2860
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
@ast
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
@en
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
@nl
type
label
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
@ast
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
@en
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
@nl
prefLabel
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
@ast
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
@en
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
@nl
P2860
P921
P3181
P356
P1476
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
@en
P2093
P2860
P304
P3181
P356
10.2147/VHRM.S33934
P407
P577
2013-01-01T00:00:00Z
2013-04-24T00:00:00Z